Open access
Open access
Powered by Google Translator Translator

Randomized Trial: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

13 Jul, 2018 | 02:33h | UTC

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cabozantinib in Hepatocellular Carcinoma – NEJM Resident 360 (free)

Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo, but the rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.